Merck & Co. Inc., of Whitehouse Station, N.J., said the FDA approved Noxafil (posaconazole) injection (18 mg/ mL), a new formulation of Noxafil for intravenous use. Merck’s antifungal agent is also marketed as Noxafil (100 mg) delayed-release tablets and Noxafil (40 mg/mL) oral suspension.